Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
CONCLUSION: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.PMID:38373832 | PMC:PMC10896667 | DOI:10.3349/ymj.2023.0229 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - February 19, 2024 Category: Universities & Medical Training Authors: Gowoon Yang Jun Won Kim Ik Jae Lee Joon Jeong Sung Gwe Ahn Soong June Bae Jee Hung Kim Yeona Cho Source Type: research

Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection
CONCLUSION: High comorbidity burden was associated with primary treatment choice, with significantly less RP and more EBRT, WW and ADT alone among men with higher levels of comorbidity. Each of the individual comorbid conditions also influenced treatment selection.PMID:38369388 | DOI:10.1016/j.clgc.2024.01.018 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 18, 2024 Category: Cancer & Oncology Authors: Tenaw Tiruye Michael O'Callaghan Liesel M FitzGerald Kim Moretti Alex Jay Braden Higgs Ganessan Kichenadasse Gillian Caughey David Roder Kerri Beckmann Source Type: research

Voxel-level dosimetry for combined Iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer
CONCLUSION: This work demonstrated the clinical feasibility of performing combined EBRT+RPT dosimetry on TPCTs. Dosimetry guides treatment decisions for EBRT and this work provides a bridge for the same paradigm to be implemented within the rapidly emerging clinical RPT space.PMID:38367914 | DOI:10.1016/j.ijrobp.2024.02.005 (Source: Cancer Control)
Source: Cancer Control - February 17, 2024 Category: Cancer & Oncology Authors: David P Adam Joseph J Grudzinski Ian R Marsh Patrick M Hill Steve Y Cho Tyler J Bradshaw Jarrod Longcor Adam Burr Justine Y Bruce Paul M Harari Bryan P Bednarz Source Type: research

Voxel-level dosimetry for combined Iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer
CONCLUSION: This work demonstrated the clinical feasibility of performing combined EBRT+RPT dosimetry on TPCTs. Dosimetry guides treatment decisions for EBRT and this work provides a bridge for the same paradigm to be implemented within the rapidly emerging clinical RPT space.PMID:38367914 | DOI:10.1016/j.ijrobp.2024.02.005 (Source: Health Physics)
Source: Health Physics - February 17, 2024 Category: Physics Authors: David P Adam Joseph J Grudzinski Ian R Marsh Patrick M Hill Steve Y Cho Tyler J Bradshaw Jarrod Longcor Adam Burr Justine Y Bruce Paul M Harari Bryan P Bednarz Source Type: research

Brachytherapy (interventional radiotherapy): The urologist opinion
Urologia. 2024 Feb 16:3915603241231355. doi: 10.1177/03915603241231355. Online ahead of print.ABSTRACTProstate cancer remains a prevalent concern worldwide, necessitating continual advancements in treatment modalities. This abstract explores the role of brachytherapy as a viable and effective option in the management of prostate cancer. Brachytherapy involves the implantation of radioactive sources directly into the prostate, providing a localized dose of radiation. n recent studies and clinical trials, brachytherapy has demonstrated promising outcomes, particularly in terms of disease control and patient outcomes. The tre...
Source: Cancer Control - February 16, 2024 Category: Cancer & Oncology Authors: Francesco Pinto Pierluigi Russo Source Type: research

Voxel-level dosimetry for combined Iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer
Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiotherapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment for patients with recurrent head and neck cancer. This work establishes a patient-specific dosimetry framework that combines Monte Carlo based dosimetry from the two radiation modalities at the voxel level using deformable image registration (DIR) and radiobiological constructs for patients enrolled in a phase I clinical trial combining EBRT and RPT. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - February 15, 2024 Category: Radiology Authors: David P. Adam, Joseph J. Grudzinski, Ian R. Marsh, Patrick M. Hill, Steve Y. Cho, Tyler J. Bradshaw, Jarrod Longcor, Adam Burr, Justine Y. Bruce, Paul M. Harari, Bryan P. Bednarz Tags: Physics Contribution Source Type: research

Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer
Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment for patients with recurrent head and neck cancer. This work establishes a patient-specific dosimetry framework that combines Monte Carlo –based dosimetry from the 2 radiation modalities at the voxel level using deformable image registration (DIR) and radiobiological constructs for patients enrolled in a phase 1 clinical trial combining EBRT and RPT. (Source: International Journal of Radiation Onco...
Source: International Journal of Radiation Oncology * Biology * Physics - February 15, 2024 Category: Radiology Authors: David P. Adam, Joseph J. Grudzinski, Ian R. Marsh, Patrick M. Hill, Steve Y. Cho, Tyler J. Bradshaw, Jarrod Longcor, Adam Burr, Justine Y. Bruce, Paul M. Harari, Bryan P. Bednarz Tags: Physics Contribution Source Type: research

Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study
ConclusionsCompared to PCa patients undergoing RP, the secondary bladder cancer was associated with EBRT, ADT, alone or in combination. The secondary colorectal cancer was also associated with receiving either EBRT, BT or ADT. (Source: Cancer Medicine)
Source: Cancer Medicine - February 14, 2024 Category: Cancer & Oncology Authors: Patricia Grisel Quintana B árcena, Armen Garo Aprikian, Alice Dragomir Tags: RESEARCH ARTICLE Source Type: research

Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The ...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Bo Seong Yun Kwang-Beom Lee Keun Ho Lee Ha Kyun Chang Joo-Young Kim Myong Cheol Lim Chel Hun Choi Hanbyoul Cho Dae-Yeon Kim Yun Hwan Kim Joong Sub Choi Chae Hyeong Lee Jae-Weon Kim Sang Wun Kim Yong Bae Kim Chi-Heum Cho Dae Gy Hong Yong Jung Song Seob Jeo Source Type: research